French ophthalmic drug specialist Nicox (Euronext Growth Paris: FR0013018124) has provided details of a poster presentation highlighting additional pre-planned analysis from the NCX 470 Mont Blanc ...
NCX 470 0.1% achieved superior IOP control compared to latanoprost 0.005%, with more patients reaching an IOP of ≤18 mmHg. The trial showed consistent IOP reduction with NCX 470, regardless of ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback